Regeneron (REGN) announces positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis
Every headline is on the live feed 20 minutes before this site.
Mail's Hodges posts, regarding UK PM Starmer, that he "...ran off the cliff today. Soon he will have to look down."
Fed Chair Nominee Warsh says Fed needs a new inflation framework and communications; interest rate tool is fairer - Q&A
Regeneron (REGN) announces positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis
Ukrainian President Zelensky says repair work on the Druzhba pipeline has completed, operations may resume
Fed Chair Nominee Warsh says US economic potential is rising, shares the confidence of US President Trump on the economy - Prepared remarks
On the Newsquawk feed at , 20 minutes before this page.
Context
Regeneron’s announcement of positive Phase 3 NIMBLE trial results for cemdisiran highlights promising advancements in their pipeline for treating generalized myasthenia gravis. This could enhance their competitive positioning in the biotech sector and potentially bolster investor sentiment towards their stock, especially if future trials continue to show efficacy. Investors should watch for its impact on revenue projections and the broader market's reaction to biotech developments.
Related headlines
- Weekly US Earnings Estimates: 19th-23rd October 2026: Earnings pick up with META, TSLA, SPCX, LRCX, and NFLX the highlights1 day ago
- Daily US Equity Opening News: 16th October 2026: TSLA gains on Roadster reveal; NFLX slips as Content Chief to leave; TRV earnings underwhelm1 day ago
- US BROKER MOVES: CPRI upgrade at Raymond James; WDAY downgraded at KeyBanc1 day ago
- US Market Wrap: Stocks hit as AI growth concerns weigh on sentiment 1 day ago
- Newsquawk Daily European Equity Opening News - 16th October 20262 days ago
- Nvidia (NVDA) expands tools for building AI-powered games with Unreal Engine 51 day ago
- Apple (AAPL) set for UK legal fight over iPhone tap-to-pay rules, FT reports1 day ago
- US EQUITY OPEN: Stocks mixed at the open as AI stock rout continues1 day ago
- US DoJ officials have reportedly signalled their preference to settle antitrust lawsuit against Apple (AAPL), The Information reports citing sources1 day ago
- US PREMARKET MOVERS: TSLA, NFLX, VRNS, AA, TRV, MSTR, WDAY, ECHO1 day ago
- Apple (AAPL) iPhone duo delivery date slips to January 25th1 day ago
- Apple's (AAPL) iPhone Duo sells out minutes after pre-orders open, according to Apple Insider1 day ago
- Nvidia's (NVDA) RTX Spark laptops have launched globally, starting at USD 2,5991 day ago
- UK CMA says that Amazon's (AMZN) AWS and Microsoft (MSFT) can do more to address cloud services barriers2 days ago
- US FAA is set to approve certification for the Boeing (BA) 737 MAX 10, sources report; potentially as soon as in the next week1 day ago
- Daily US Earnings Estimates: 19th October 2026: FITB, WRB, and STLD1 day ago
- US officials pressed Beijing on market access issues for Mastercard (MA) and Citigroup (C) during at least two bilateral meetings with Chinese counterparts in Bangkok this week, CNBC reports, citing a source1 day ago
- Charles Schwab (SCHW) CEO says seeing record levels of interest in fixed income; Brokerage is blocking unauthorised AI agents1 day ago
- ExxonMobil (XOM) says changes in margins to impact Q3 chemical products earnings by USD -0.6bln Q/Q1 day ago
- Travelers (TRV) Q3 2026 (USD): Adj. EPS 9.18 (exp. 7.39), Revenue 12.4bln (exp. 11.4bln); Net Premiums Written 11.48bln (exp. 11.40bln), Catastrophe Loss 538mln (exp. 695mln)1 day ago
The feed had this first.
Use the Platform